EUVIMEDEUVIMED entdecken
Multizentrische Studie

Prognostic model for second progression‐free survival and overall survival in patients with high‐risk metastatic hormone‐sensitive prostate cancer treated with abiraterone acetate and androgen deprivation therapy

Shintaro Narita iD, Takafumi Yanagisawa iD, Shingo Hatakeyama, Kenichi Hata, Kazutoshi Fujita, Takashi Ueda, Toshikazu Tanaka, Shinya Maita, Shuji Chiba, Hiromi Sato, Yuya Sekine, Mizuki Kobayashi und 17 weitere

The Prostate · 2025-01 · 85 (1) · 73-81

DOI: 10.1002/pros.24802 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift The Prostate, online erschienen am 30.09.2024. Verfasst von Shintaro Narita und 28 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Akita University Graduate School of Medicine, Akita, Japan. Hauptthemen laut MEDLINE: Abiraterone Acetate, Prostatic Neoplasms, Androgen Antagonists, Progression-Free Survival. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

To develop and validate a prognostic risk model for high‐risk metastatic hormone‐sensitive prostate cancer (mHSPC) patients treated with upfront abiraterone acetate (ABI).

Methods

This retrospective multicenter study involved 233 high‐risk mHSPC patients who received upfront ABI, developed by three academic centers. The model was externally validated with an independent cohort of 282 patients. To identify independent prognostic factors for second progression‐free survival (PFS2) and develop the best‐fitted model, Cox proportional hazards regression, followed by the Akaike information criterion, was used. Patients were categorized into three groups based on their risk scores. PFS2 and overall survival (OS) were evaluated according to the risk groups in the discovery and validation cohorts.

Results

The median age was 72 (range 51–89) years, with a median follow‐up duration of 27 months. Independent factors linked to PFS2 included an Eastern Cooperative Oncology Group performance status ≥2, a primary Gleason score of 5, an extent of disease score of ≥3 or liver metastasis, and lactate dehydrogenase >220 U/L. Median PFS2 for favorable‐, intermediate‐, and poor‐risk groups were not reached, 43 months, and 16 months, respectively. The median OS was 29 months in the poor‐risk group, whereas it was not reached in the favorable‐ and intermediate‐risk groups. The 2‐year OS rates in the favorable‐, intermediate‐ and poor‐risk groups were 94.5%, 80.1%, and 60.3%, respectively. The validation cohort confirmed the risk model's relationship with PFS2 and OS. The median PFS2 and OS in the high‐risk group were 21 months and 32 months, respectively.

Conclusions

Our prognostic model, including five clinical factors, is useful for patient care and treatment selection in high‐risk mHSPC patients treated with ADT plus ABI. The developed model could provide more accurate information, guide treatment decisions, or classify patients in future clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Abiraterone AcetateProstatic NeoplasmsAndrogen AntagonistsProgression-Free SurvivalHumansMaleAgedRetrospective StudiesAged, 80 and overMiddle AgedPrognosisNeoplasm Metastasis

Stichwörter der Autor:innen

abiraterone acetatehormone‐sensitivemetastaticprognosisprostate cancersurvival

Substanzen

Abiraterone AcetateAndrogen Antagonists

Autor:innen und Institutionen

  • Department of Urology, Akita University Graduate School of Medicine, Akita, Japan.
  • Department of Urology, The Jikei University School of Medicine, Tokyo, Japan.
  • Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
  • Department of Urology, Atsugi City Hospital, Kanagawa, Japan.
  • Department of Urology, Kindai University, Faculty of Medicine, Osakasayama, Osaka, Japan.
  • Department of Urology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto‑City, Kyoto, Japan.

ORCID-Profile: Shintaro Narita, Takafumi Yanagisawa, Soki Kashima, Osamu Ukimura

Förderung

  • Japan Society for the Promotion of Science

Zitieren

APA

Narita, S., Yanagisawa, T., Hatakeyama, S., Hata, K., Fujita, K., Ueda, T., Tanaka, T., Maita, S., Chiba, S., Sato, H., Sekine, Y., Kobayashi, M., Kashima, S., Yamamoto, R., Numakura, K., Saito, M., Takayama, K., Okane, K., Ishida, T., …, & Habuchi, T. (2025). Prognostic model for second progression‐free survival and overall survival in patients with high‐risk metastatic hormone‐sensitive prostate cancer treated with abiraterone acetate and androgen deprivation therapy. The Prostate, 85(1), 73-81. https://doi.org/10.1002/pros.24802

Vancouver

Narita S, Yanagisawa T, Hatakeyama S, Hata K, Fujita K, Ueda T, et al. Prognostic model for second progression‐free survival and overall survival in patients with high‐risk metastatic hormone‐sensitive prostate cancer treated with abiraterone acetate and androgen deprivation therapy. The Prostate. 2025;85(1):73-81. doi:10.1002/pros.24802

BibTeX
@article{Narita2025,
  author = {Narita, Shintaro and Yanagisawa, Takafumi and Hatakeyama, Shingo and Hata, Kenichi and Fujita, Kazutoshi and Ueda, Takashi and Tanaka, Toshikazu and Maita, Shinya and Chiba, Shuji and Sato, Hiromi and Sekine, Yuya and Kobayashi, Mizuki and Kashima, Soki and Yamamoto, Ryohei and Numakura, Kazuyuki and Saito, Mitsuru and Takayama, Koichiro and Okane, Katsumi and Ishida, Toshiya and Horikawa, Yohei and Kumazawa, Teruaki and Shimoda, Jiro and Iwabuchi, Ikuya and Suzuki, Takehiro and Ukimura, Osamu and Kimura, Takahiro and Ohyama, Chikara and Nomura, Kyoko and Habuchi, Tomonori},
  title = {Prognostic model for second progression‐free survival and overall survival in patients with high‐risk metastatic hormone‐sensitive prostate cancer treated with abiraterone acetate and androgen deprivation therapy},
  journal = {The Prostate},
  year = {2025},
  volume = {85},
  number = {1},
  pages = {73--81},
  doi = {10.1002/pros.24802}
}
Kostenlos starten →